These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24412647)

  • 1. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liraglutide in polycystic ovary syndrome].
    Gómez-Pérez AM; Fernández-García JC; Mancha Doblas I; Tinahones FJ
    Med Clin (Barc); 2014 Sep; 143(6):283-4. PubMed ID: 24456922
    [No Abstract]   [Full Text] [Related]  

  • 5. Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
    García de Lucas MD; Olalla Sierra J; Piña Fernández J
    Diabetes Metab; 2015 Feb; 41(1):102-3. PubMed ID: 25455831
    [No Abstract]   [Full Text] [Related]  

  • 6. [Liraglutide reduces biomarkers and vascular risk in patients with diabetes mellitus type 2].
    García de Lucas MD; Olalla J; Sempere M
    Rev Med Chil; 2013 Dec; 141(12):1602-4. PubMed ID: 24728441
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of obesity with liraglutide. NN8022-1807 study].
    Scherbaum WA; Nitschmann S
    Internist (Berl); 2010 Aug; 51(8):1064-6. PubMed ID: 20628715
    [No Abstract]   [Full Text] [Related]  

  • 8. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May; 48(5):50-3. PubMed ID: 20447980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
    de Luis DA; Ovalle HF; Soto GD; Izaola O; de la Fuente B; Romero E
    J Investig Med; 2014 Feb; 62(2):324-7. PubMed ID: 24322329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
    Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R
    Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
    Gross B
    J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current challenges in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():1-3. PubMed ID: 22405263
    [No Abstract]   [Full Text] [Related]  

  • 14. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes.
    Ishøy PL; Knop FK; Vilsbøll T; Glenthøj BY; Ebdrup BH
    Am J Psychiatry; 2013 Jun; 170(6):681-2. PubMed ID: 23732970
    [No Abstract]   [Full Text] [Related]  

  • 16. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide in the management of type 2 diabetes.
    Wajcberg E; Amarah A
    Drug Des Devel Ther; 2010 Oct; 4():279-90. PubMed ID: 21116334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of liraglutide on male fertility: a case report.
    Fontoura P; Cardoso MC; Erthal-Martins MC; Werneck C; Sartorio C; Ramos CF
    Reprod Biomed Online; 2014 Nov; 29(5):644-6. PubMed ID: 25246122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.